Iterative Health Secures $77M Series C to Expand AI-Powered Clinical Trial Network
核心洞察
Iterative Health raised $77 million in Series C funding led by Google Ventures (搜索) and Intrepid Growth Partners (搜索) to scale its AI-powered clinical research network platform.
The company plans to expand its platform applications from gastroenterology and hepatology into cardiology and obesity (搜索) therapeutic areas while growing its geographic reach.
Iterative's network currently includes over 100 research sites across four continents and partnerships with more than 40 biotech, pharma, medical device companies and CROs.
Iterative Health has secured $77 million in Series C funding to expand and scale its artificial intelligence-powered clinical research network, addressing persistent recruitment challenges that plague clinical trial sponsors. The financing round was led by Google Ventures (搜索) and Intrepid Growth Partners (搜索).
Platform Expansion Into High-Growth Therapeutic Areas
Through this funding, Iterative will expand its clinical research network platform applications into cardiology and obesity (搜索), which represent areas of strong growth for pharmaceutical companies. The platform currently operates across gastroenterology and hepatology segments, utilizing AI-powered technology to provide trial operators with centralized access to clinical trial sites featuring diverse patient populations.
The company's network currently comprises more than 100 research sites spanning four continents. Iterative has established partnerships with over 40 biotech, pharmaceutical, medical device companies and contract research organizations (CROs), enabling users to achieve faster site activation and patient enrollment rates according to the company.
Leadership and Governance Changes
The funding round brings strategic leadership additions to Iterative's governance structure. Intrepid Growth Partners (搜索) co-founder Ajay Agrawal will join Iterative's board of directors, while Google Ventures (搜索) general partner Anthony Philippakis will serve as a board observer.
Addressing Clinical Trial Recruitment Bottlenecks
Trial recruitment represents one of the most significant bottlenecks affecting sponsors, as identifying suitable study sites with appropriate patient populations poses considerable challenges. This issue is particularly pronounced for ethnic minority groups, pregnant individuals, and trans/non-binary patients, who remain typically underrepresented in clinical studies.
Global regulatory agencies have intensified efforts to address representation gaps in clinical trials. Both the US Food and Drug Administration (搜索) (FDA) and the European Medicines Agency (搜索) (EMA) have issued guidance encouraging diverse representation within clinical trials in recent years. The World Health Organization (WHO) has published similar guidance targeting the inclusion of participants from ethnic minorities, LGBTQI+ communities, age extremes, pregnant and lactating individuals, and patients from lower socioeconomic backgrounds.
Industry Progress Toward Trial Equity
During a panel discussion at Arena International's Outsourcing in Clinical Trials DACH conference in November 2025, experts noted that equity in clinical trials is advancing. However, they identified that governance and implementation of guidelines intended to achieve this goal vary significantly at regional and institutional levels, representing a challenge that must be overcome to achieve true equity in clinical research.